Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\29623110
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Ther+Adv+Med+Oncol
2018 ; 10
(ä): 1758835918764628
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Clinical assessment of immune-related adverse events
#MMPMID29623110
Sosa A
; Lopez Cadena E
; Simon Olive C
; Karachaliou N
; Rosell R
Ther Adv Med Oncol
2018[]; 10
(ä): 1758835918764628
PMID29623110
show ga
Immunotherapy through checkpoint inhibitors is now standard practice for a
growing number of cancer types, supported by overall improvement of clinical
outcomes and better tolerance. One anti-CTLA-4 antibody (ipilimumab), two
anti-PD-1 antibodies (pembrolizumab and nivolumab) and three anti-PD-L1
antibodies (atezolizumab, avelumab and durvalumab) have been approved for clear
benefits across diverse trials. Adverse events of an immune nature associated
with these agents frequently affect the skin, colon, endocrine glands, lungs and
liver. Most of these effects are mild and can be managed through transient
immunosuppression with corticosteroids, but high-grade events often require
hospitalization and specialized treatment. However, since immunotherapy is
recent, physicians with clinical experience in the diagnosis and management of
immune toxicities are frequently those who actively participated in trials, but
many practicing oncologists are still not familiarized with the assessment of
these events. This review focuses on the incidence, diagnostic assessment and
recommended management of the most relevant immune-related adverse events.
free
free
free
